Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments

Riccardo V. D'Elia, Stuart Woods, Wendy Butcher, Jonathan McGahon, Swapnil Khadke, Yvonne Perrie, E. Diane Williamson, Craig W. Roberts

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is recalcitrant to antibiotic therapy. There also is currently no licensed vaccine for this potentially fatal pathogen, further highlighting the requirement for better therapeutics to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome to entrap already- licensed antibiotics. Bilosome-entrapped antibiotics were used to treat mice infected via the aerosol route with B. pseudomallei. When treatment was started by the oral route at 6 h post-infection and continued for 7 days, bilosome levofloxacin and bilosome doxycycline formulations were significantly more efficacious than free antibiotics in terms of survival rates. Additionally, bilosome formulated levofloxacin protected mice from antibiotic and infection induced weight loss following B. pseudomallei infection. The microbiomes of mice treated with levofloxacin were depleted of all phyla with the exception of Firmicutes, but doxycycline treatment had minimal effect on the microbiome. Encapsulation of either drug in bilosomes had no deleterious or clear advantageous effect on microbiome. This indicates that the ability of bilosomes to ameliorate antibiotic induced weight loss is not due to microbiome effects. The bilosome platform not only has potential to reduce adverse effects of orally delivered antimicrobials, but has potential for other therapeutics which may cause detrimental side-effects or require enhanced delivery.
LanguageEnglish
Pages202-212
Number of pages11
JournalJournal of Controlled Release
Volume298
Early online date4 Feb 2019
DOIs
Publication statusPublished - 28 Mar 2019

Fingerprint

Melioidosis
Microbiota
Burkholderia pseudomallei
Anti-Bacterial Agents
Technology
Levofloxacin
Doxycycline
Weight Loss
Burkholderia Infections
Infection
Aerosols
Gram-Negative Bacteria
Therapeutics
Vaccines
Pharmaceutical Preparations

Keywords

  • encapsulation
  • vesicles
  • bilosomes
  • oral delivery
  • antibiotics
  • Burkholderia pseudomallei

Cite this

@article{1cde11d896ee41f49ea6553e59efccc3,
title = "Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments",
abstract = "Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is recalcitrant to antibiotic therapy. There also is currently no licensed vaccine for this potentially fatal pathogen, further highlighting the requirement for better therapeutics to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome to entrap already- licensed antibiotics. Bilosome-entrapped antibiotics were used to treat mice infected via the aerosol route with B. pseudomallei. When treatment was started by the oral route at 6 h post-infection and continued for 7 days, bilosome levofloxacin and bilosome doxycycline formulations were significantly more efficacious than free antibiotics in terms of survival rates. Additionally, bilosome formulated levofloxacin protected mice from antibiotic and infection induced weight loss following B. pseudomallei infection. The microbiomes of mice treated with levofloxacin were depleted of all phyla with the exception of Firmicutes, but doxycycline treatment had minimal effect on the microbiome. Encapsulation of either drug in bilosomes had no deleterious or clear advantageous effect on microbiome. This indicates that the ability of bilosomes to ameliorate antibiotic induced weight loss is not due to microbiome effects. The bilosome platform not only has potential to reduce adverse effects of orally delivered antimicrobials, but has potential for other therapeutics which may cause detrimental side-effects or require enhanced delivery.",
keywords = "encapsulation, vesicles, bilosomes, oral delivery, antibiotics, Burkholderia pseudomallei",
author = "D'Elia, {Riccardo V.} and Stuart Woods and Wendy Butcher and Jonathan McGahon and Swapnil Khadke and Yvonne Perrie and Williamson, {E. Diane} and Roberts, {Craig W.}",
year = "2019",
month = "3",
day = "28",
doi = "10.1016/j.jconrel.2019.02.002",
language = "English",
volume = "298",
pages = "202--212",
journal = "Journal of Controlled Release",
issn = "0168-3659",

}

TY - JOUR

T1 - Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments

AU - D'Elia, Riccardo V.

AU - Woods, Stuart

AU - Butcher, Wendy

AU - McGahon, Jonathan

AU - Khadke, Swapnil

AU - Perrie, Yvonne

AU - Williamson, E. Diane

AU - Roberts, Craig W.

PY - 2019/3/28

Y1 - 2019/3/28

N2 - Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is recalcitrant to antibiotic therapy. There also is currently no licensed vaccine for this potentially fatal pathogen, further highlighting the requirement for better therapeutics to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome to entrap already- licensed antibiotics. Bilosome-entrapped antibiotics were used to treat mice infected via the aerosol route with B. pseudomallei. When treatment was started by the oral route at 6 h post-infection and continued for 7 days, bilosome levofloxacin and bilosome doxycycline formulations were significantly more efficacious than free antibiotics in terms of survival rates. Additionally, bilosome formulated levofloxacin protected mice from antibiotic and infection induced weight loss following B. pseudomallei infection. The microbiomes of mice treated with levofloxacin were depleted of all phyla with the exception of Firmicutes, but doxycycline treatment had minimal effect on the microbiome. Encapsulation of either drug in bilosomes had no deleterious or clear advantageous effect on microbiome. This indicates that the ability of bilosomes to ameliorate antibiotic induced weight loss is not due to microbiome effects. The bilosome platform not only has potential to reduce adverse effects of orally delivered antimicrobials, but has potential for other therapeutics which may cause detrimental side-effects or require enhanced delivery.

AB - Burkholderia pseudomallei is a Gram-negative intracellular bacterium which is recalcitrant to antibiotic therapy. There also is currently no licensed vaccine for this potentially fatal pathogen, further highlighting the requirement for better therapeutics to treat the disease melioidosis. Here we use an oral delivery platform, the bilosome to entrap already- licensed antibiotics. Bilosome-entrapped antibiotics were used to treat mice infected via the aerosol route with B. pseudomallei. When treatment was started by the oral route at 6 h post-infection and continued for 7 days, bilosome levofloxacin and bilosome doxycycline formulations were significantly more efficacious than free antibiotics in terms of survival rates. Additionally, bilosome formulated levofloxacin protected mice from antibiotic and infection induced weight loss following B. pseudomallei infection. The microbiomes of mice treated with levofloxacin were depleted of all phyla with the exception of Firmicutes, but doxycycline treatment had minimal effect on the microbiome. Encapsulation of either drug in bilosomes had no deleterious or clear advantageous effect on microbiome. This indicates that the ability of bilosomes to ameliorate antibiotic induced weight loss is not due to microbiome effects. The bilosome platform not only has potential to reduce adverse effects of orally delivered antimicrobials, but has potential for other therapeutics which may cause detrimental side-effects or require enhanced delivery.

KW - encapsulation

KW - vesicles

KW - bilosomes

KW - oral delivery

KW - antibiotics

KW - Burkholderia pseudomallei

UR - http://www.scopus.com/inward/record.url?scp=85062109957&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2019.02.002

DO - 10.1016/j.jconrel.2019.02.002

M3 - Article

VL - 298

SP - 202

EP - 212

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -